Skip to main content

Site notifications

CHMP recommendations for the pharmacovigilance plan as part of the Risk Management Plan to be submitted with the marketing authorisation application for a pandemic influenza vaccine

We have adopted this International Scientific Guideline - EMEA/359381/2009.

Last updated